| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Departments of Surgery, Orthopaedic Service [W. G., J. H. H.], Pediatrics [P. A. M., R. G.], Human Genetics [M. L.], Pathology [M. L., A. G. H.], and Molecular Pharmacology and Experimental Therapeutics [J. R. B.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021
High-dose methotrexate is a major component of current protocols for the treatment of osteosarcoma, but some tumors seem to be resistant. Potential mechanisms of resistance include decreased transport through the reduced folate carrier (RFC) and increased expression of dihydrofolate reductase (DHFR). To investigate methotrexate resistance, tumors were obtained from 42 patients with high-grade osteosarcoma. RFC and DHFR mRNA expression were studied by semiquantitative reverse transcription-PCR. The RFC and DHFR genes were studied for deletions and amplification by Southern blot. Thirteen of 20 (65%) osteosarcoma samples were found to have decreased RFC expression at the time of initial biopsy. At definitive surgery and relapse, 10 of 22 (45%) were found to have decreased RFC expression. Seventeen of 26 (65%) samples with a poor response to chemotherapy had decreased RFC expression, whereas 5 of 14 (36%) samples with a good response had a decrease (P = 0.03). None of the samples had an RFC gene deletion. Two of 20 samples (10%) showed increased DHFR expression at initial biopsy. The frequency of increased DHFR expression was significantly higher in metastatic or recurrent tumors (62%, P = 0.014). None of the samples showed evidence of DHFR gene amplification. The high frequency of decreased RFC expression in the biopsy material suggests that impaired transport of methotrexate is a common mechanism of intrinsic resistance in osteosarcoma. Increased DHFR expression in the pulmonary metastases may be a mechanism of acquired methotrexate resistance or a difference between primary and metastatic lesions.
This article has been cited by other articles:
|
|
 |
|
  R. Zhao, A. Qiu, E. Tsai, M. Jansen, M. H. Akabas, and I. D. Goldman The Proton-Coupled Folate Transporter: Impact on Pemetrexed Transport and on Antifolates Activities Compared with the Reduced Folate Carrier Mol. Pharmacol., September 1, 2008; 74(3): 854 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Scionti, F. Michelacci, M. Pasello, C. M. Hattinger, M. Alberghini, M. C. Manara, G. Bacci, S. Ferrari, K. Scotlandi, P. Picci, et al. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma Ann. Onc., August 1, 2008; 19(8): 1500 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Deng, Z. Hou, L. Wang, C. Cherian, J. Wu, A. Gangjee, and L. H. Matherly Role of Lysine 411 in Substrate Carboxyl Group Binding to the Human Reduced Folate Carrier, as Determined by Site-Directed Mutagenesis and Affinity Inhibition Mol. Pharmacol., April 1, 2008; 73(4): 1274 - 1281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Yang, E. A. Kolb, J. Qin, A. Chou, R. Sowers, B. Hoang, J. H. Healey, A. G. Huvos, P. A. Meyers, and R. Gorlick The Folate Receptor {alpha} Is Frequently Overexpressed in Osteosarcoma Samples and Plays a Role in the Uptake of the Physiologic Substrate 5-Methyltetrahydrofolate Clin. Cancer Res., May 1, 2007; 13(9): 2557 - 2567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Neuzil, M. Tomasetti, Y. Zhao, L.-F. Dong, M. Birringer, X.-F. Wang, P. Low, K. Wu, B. A. Salvatore, and S. J. Ralph Vitamin E Analogs, a Novel Group of "Mitocans," as Anticancer Agents: The Importance of Being Redox-Silent Mol. Pharmacol., May 1, 2007; 71(5): 1185 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ge, C. L. Haska, K. LaFiura, M. Devidas, S. B. Linda, M. Liu, R. Thomas, J. W. Taub, and L. H. Matherly Prognostic Role of the Reduced Folate Carrier, the Major Membrane Transporter for Methotrexate, in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group Clin. Cancer Res., January 15, 2007; 13(2): 451 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Hou, J. Ye, C. L. Haska, and L. H. Matherly Transmembrane Domains 4, 5, 7, 8, and 10 of the Human Reduced Folate Carrier Are Important Structural or Functional Components of the Transmembrane Channel for Folate Substrates J. Biol. Chem., November 3, 2006; 281(44): 33588 - 33596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Gomez, S. L. Santillana, C. S. Vallejos, R. Velarde, J. Sanchez, X. Wang, N. L. Bauer, R. D. Hockett, V. J. Chen, C. Niyikiza, et al. A Phase II Trial of Pemetrexed in Advanced Breast Cancer: Clinical Response and Association with Molecular Target Expression Clin. Cancer Res., February 1, 2006; 12(3): 832 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rothem, B. Berman, M. Stark, G. Jansen, and Y. G. Assaraf The Reduced Folate Carrier Gene Is a Novel Selectable Marker for Recombinant Protein Overexpression Mol. Pharmacol., September 1, 2005; 68(3): 616 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Spees, T. P.F. Gade, G. Yang, W. P. Tong, W. G. Bornmann, R. Gorlick, and J. A. Koutcher An 19F Magnetic Resonance-Based In Vivo Assay of Solid Tumor Methotrexate Resistance: Proof of Principle Clin. Cancer Res., February 15, 2005; 11(4): 1454 - 1461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Marina, M. Gebhardt, L. Teot, and R. Gorlick Biology and Therapeutic Advances for Pediatric Osteosarcoma Oncologist, July 1, 2004; 9(4): 422 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rothem, M. Stark, Y. Kaufman, L. Mayo, and Y. G. Assaraf Reduced Folate Carrier Gene Silencing in Multiple Antifolate-resistant Tumor Cell Lines Is Due to a Simultaneous Loss of Function of Multiple Transcription Factors but Not Promoter Methylation J. Biol. Chem., January 2, 2004; 279(1): 374 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Serra, G. Reverter-Branchat, D. Maurici, S. Benini, J.-N. Shen, T. Chano, C.-M. Hattinger, M.-C. Manara, M. Pasello, K. Scotlandi, et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells Ann. Onc., January 1, 2004; 15(1): 151 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gorlick, P. Anderson, I. Andrulis, C. Arndt, G. P. Beardsley, M. Bernstein, J. Bridge, N.-K. Cheung, J. S. Dome, D. Ebb, et al. Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary Clin. Cancer Res., November 15, 2003; 9(15): 5442 - 5453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sowers, J. Toguchida, J. Qin, P. A. Meyers, J. H. Healey, A. Huvos, D. Banerjee, J. R. Bertino, and R. Gorlick mRNA Expression Levels of E2F Transcription Factors Correlate with Dihydrofolate Reductase, Reduced Folate Carrier, and Thymidylate Synthase mRNA Expression in Osteosarcoma Mol. Cancer Ther., June 1, 2003; 2(6): 535 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rothem, A. Aronheim, and Y. G. Assaraf Alterations in the Expression of Transcription Factors and the Reduced Folate Carrier as a Novel Mechanism of Antifolate Resistance in Human Leukemia Cells J. Biol. Chem., March 7, 2003; 278(11): 8935 - 8941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Yang, R. Sowers, B. Mazza, J. H. Healey, A. Huvos, H. Grier, M. Bernstein, G. P. Beardsley, M. D. Krailo, M. Devidas, et al. Sequence Alterations in the Reduced Folate Carrier Are Observed in Osteosarcoma Tumor Samples Clin. Cancer Res., February 1, 2003; 9(2): 837 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Whetstine, T. L. Witt, and L. H. Matherly The Human Reduced Folate Carrier Gene Is Regulated by the AP2 and Sp1 Transcription Factor Families and a Functional 61-Base Pair Polymorphism J. Biol. Chem., November 8, 2002; 277(46): 43873 - 43880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sadlish, F. M. R. Williams, and W. F. Flintoff Functional Role of Arginine 373 in Substrate Translocation by the Reduced Folate Carrier J. Biol. Chem., October 25, 2002; 277(44): 42105 - 42112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. D. Goldman Membrane Transport of Chemotherapeutics and Drug Resistance: Beyond the ABC Family of Exporters to the Role of Carrier-mediated Processes Clin. Cancer Res., January 1, 2002; 8(1): 4 - 6. [Full Text] [PDF]
|
|
|
|
|
|
J. Worm, A. F. Kirkin, K. N. Dzhandzhugazyan, and P. Guldberg Methylation-dependent Silencing of the Reduced Folate Carrier Gene in Inherently Methotrexate-resistant Human Breast Cancer Cells J. Biol. Chem., October 19, 2001; 276(43): 39990 - 40000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Takeshita, K. Kusuzaki, T. Ashihara, M. C. Gebhardt, H. J. Mankin, and Y. Hirasawa Intrinsic Resistance to Chemotherapeutic Agents in Murine Osteosarcoma Cells J. Bone Joint Surg. Am., July 1, 2000; 82(7): 963 - 963. [Abstract] [Full Text]
|
|
|
|
|
|
J. R. Whetstine and L. H. Matherly The Basal Promoters for the Human Reduced Folate Carrier Gene Are Regulated by a GC-box and a cAMP-response Element/AP-1-like Element. BASIS FOR TISSUE-SPECIFIC GENE EXPRESSION J. Biol. Chem., February 23, 2001; 276(9): 6350 - 6358. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
